Tag: large-cap
Amgen Stock Analysis: Buy or Sell? Valuation, Cash Flow & Debt
Amgen (AMGN) is rated Hold because strong cash generation supports the business, but the valuation already reflects much of that quality. The key concern is elevated debt and policy-driven pricing pressure, which limit upside despite a 35.6% operating margin and solid free cash flow.
Copart Stock Analysis: Buy or Sell? Valuation, Cash Flow & Growth
Copart (CPRT) is rated Hold as strong cash generation and high margins are offset by slow 2.4% TTM growth and a valuation that is fair, not cheap. The key watchpoint is whether growth can re-accelerate enough to justify a rerating.
Agnico Eagle Mines Stock Analysis: Buy or Sell? Valuation & Cash Flow
Agnico Eagle Mines Limited (AEM) is rated Hold as strong margins and cash generation are already priced in. The stock’s premium valuation leaves limited room for error if revenue growth keeps cooling.
Colgate-Palmolive Stock Analysis: Buy or Sell? Valuation, Margins & Cash Flow
Colgate-Palmolive (CL) is rated Hold as its quality franchise and strong margins are already reflected in the share price. The stock trades at a fair valuation, while leverage and a 1.0x current ratio limit the margin of safety.
Marathon Petroleum Stock Analysis: Buy or Sell? Valuation, Leverage & FCF
Marathon Petroleum (MPC) is rated Hold as strong cash generation and 13.6% operating margin are already reflected in the share price. The case hinges on whether EBITDA and free cash flow stay elevated while 1.7x net debt to EBITDA limits upside.
Boston Scientific Stock Analysis: Buy or Sell? Valuation & Growth Outlook
Boston Scientific (BSX) is rated Hold as strong organic growth and clinical momentum are offset by a valuation that already reflects much of the upside. The key question is whether BSX can keep growing fast enough to justify 13.4x EV/EBITDA while managing a $12.6B debt load.
Stryker Stock Analysis: Buy or Sell? Valuation, Margins & Risk
Stryker (SYK) is a HOLD as strong margins and free cash flow support the business, but the valuation already discounts much of that quality. Execution risk, including insider selling and a cyber incident, keeps the setup from looking cheap.
Northrop Grumman Stock Analysis: Buy or Sell? Backlog, Margins & Free Cash Flow
Northrop Grumman (NOC) is rated Hold as its defense franchise and $95.7B backlog are already reflected in the share price. Free cash flow is strong, but 84% U.S. government revenue concentration and the need for better margin expansion keep the setup balanced.
Quanta Services Stock Analysis: Buy or Sell? Valuation & Free Cash Flow
Quanta Services (PWR) is rated Hold as rapid growth supports the business, but the stock already embeds a lot of that optimism. Rich valuation and a thin free-cash-flow yield leave limited room for disappointment.
CME Group Stock Analysis: Buy or Sell? Valuation & Cash Flow
CME Group (CME) is rated Hold as its elite clearing franchise and strong cash generation are offset by a rich valuation. The stock screens well on free cash flow and leverage, but slow revenue growth leaves limited room for multiple expansion.